Genglycos Kit
Product Images NDC 69794-333

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Genglycos (NDC 69794-333). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ultragenyx Pharmaceutical Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (2 Vial Kit Label)

Label for GENGLYCOS (pariglasgene brecaparvovec-opnr) kit, NDC 69794-333-03, intended for patient weight 15 to less than 21 kg. The kit contains three 2 mL vials. Manufacturer: Ultragenyx Pharmaceutical Inc. Includes a barcode and product identification numbers.*

FDA Label Image

Principal Display Panel (2 Vial Kit Label)

Label for GENGLYCOS kit containing pariglasgene brecaparvovec-opnr by Ultragenyx Pharmaceutical Inc. The label specifies NDC 69794-334-04 and indicates the kit is for patients weighing 21 to less than 27 kg. Kit contents include 4 vials of 2 mL each. A barcode is also present on the label.*

FDA Label Image

Principal Display Panel (2 Vial Kit Label)

Packaging label for GENGLYCOS kit containing pariglasgene brecaparvovec-opnr by Ultragenyx Pharmaceutical Inc. The label indicates the kit is for patients weighing 27 to less than 33 kg and includes 5 vials of 2 mL each. The NDC number is 69794-335-05, and a barcode is also visible.*

FDA Label Image

Principal Display Panel (2 Vial Kit Label)

Label for GENGLYCOS (pariglasgene brecaparvovec-opnr) kit indicating it is for patients weighing 33 to less than 39 kg. The kit contains 6 vials, each with a volume of 2 mL. The label includes the NDC 69794-336-06 and a barcode. The product is by Ultragenyx Pharmaceutical Inc.*

FDA Label Image

Principal Display Panel (2 Vial Kit Label)

Label of GENGLYCOS kit containing pariglasgene brecaparvovec-opnr for human prescription use by Ultragenyx Pharmaceutical Inc. The kit is intended for patients weighing 39 to less than 45 kg and includes 7 vials of 2 mL each. The label also shows the NDC 69794-337-07 and a barcode.*

FDA Label Image

Principal Display Panel (2 Vial Kit Label)

Packaging label for GENGLYCOS pariglasgene brecaparvovec-opnr HUMAN PRESCRIPTION DRUG kit by Ultragenyx Pharmaceutical Inc. The label shows patient weight range 45 to less than 51 kg and kit contents as 8 vials of 2 mL each. Also displays the NDC number 69794-338-08 alongside a barcode.*

FDA Label Image

Principal Display Panel (2 Vial Kit Label)

Label for GENGLYCOS (pariglasgene brecaparvovec-opnr) kit from Ultragenyx Pharmaceutical Inc. The label shows NDC 69794-339-09 and specifies the kit is for patients weighing 51 to less than 57 kg. Kit contents include 9 vials of 2 mL each. Barcode is present on the right side.*

FDA Label Image

Principal Display Panel (2 Vial Kit Label)

Label for GENGLYCOS kit containing pariglasgene brecaparvovec-opnr with NDC 69794-340-10. The label indicates the kit is intended for patients weighing 57 to less than 63 kg and contains 10 vials of 2 mL each. The label also features a barcode and the labeler Ultragenyx Pharmaceutical Inc.*

FDA Label Image

Principal Display Panel (2 Vial Kit Label)

Label for GENGLYCOS kit containing pariglasgene brecaparvovec-opnr. The label details patient weight group 63 to <69 kg and specifies kit contents as 11 vials of 2 mL each. The label also includes the NDC number 69794-341-11 and a barcode. The labeler is Ultragenyx Pharmaceutical Inc.*

FDA Label Image

Principal Display Panel (2 Vial Kit Label)

Label for GENGLYCOS kit containing pariglasgene brecaparvovec-opnr. The label specifies patient weight range as 69 to less than 75 kg and kit contents of 12 vials each containing 2 mL. The label includes an NDC number and a barcode. Labeler is Ultragenyx Pharmaceutical Inc.*

FDA Label Image

Principal Display Panel (2 Vial Kit Label)

Label for GENGLYCOS pariglasgene brecaparvovec-opnr kit by Ultragenyx Pharmaceutical Inc. The label specifies a patient weight range of 75 to less than 81 kg and kit contents of 13 vials, each containing 2 mL. The NDC 69794-343-13 and a barcode are also visible.*

FDA Label Image

Principal Display Panel (2 Vial Kit Label)

Label for GENGLYCOS pariglasgene brecaparvovec-opnr kit by Ultragenyx Pharmaceutical Inc. The label specifies patient weight range of 81 to less than 87 kg and kit contents of 14 vials, each 2 mL. The NDC is 69794-344-14 and includes a barcode.*

FDA Label Image

Principal Display Panel (2 Vial Kit Label)

Label for GENGLYCOS kit containing pariglasgene brecaparvovec-opnr, indicated for patients weighing 87 kg or more. The kit includes 15 vials, each with 2 mL. The label shows the NDC number 69794-345-15 and a barcode, with Ultragenyx Pharmaceutical Inc. as the labeler.*

FDA Label Image

Principal Display Panel (2 Vial Kit Label)

Label for GENGLYCOS pariglasgene brecaparvovec-opnr, a human prescription drug kit by Ultragenyx Pharmaceutical Inc. It specifies a dosage form of 2 mL suspension for intravenous infusion with a concentration of 3 x 10^13 genome copies/mL. The label includes storage instructions to keep frozen at or below -60°C (-76°F), with warnings to not shake or refreeze the single-dose vial.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for GENGLYCOS kit containing pariglasgene brecaparvovec-opnr, suspension for intravenous infusion with a concentration of 3 x 10^13 genome copies/mL. The label indicates storage instructions to keep frozen below -60°C, avoiding shaking and refreezing, and is marked Rx only for single-dose vials. Manufactured by Ultragenyx Pharmaceutical Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.